<DOC>
	<DOCNO>NCT00101101</DOCNO>
	<brief_summary>RATIONALE : Vaccines make gene-modified cell person 's cancer cell may make body build effective immune response kill cancer cell . Interleukin-2 ( IL-2 ) may stimulate white blood cell kill cancer cell . Giving booster vaccination may make strong immune response prevent delay recurrence cancer . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Giving vaccine therapy together IL-2 combination chemotherapy may effective treatment mantle cell lymphoma . PURPOSE : This phase II trial study well give vaccine therapy together IL-2 combination chemotherapy work treat patient relapse de novo stage II , stage III , stage IV mantle cell lymphoma .</brief_summary>
	<brief_title>Universal Granulocyte Macrophage-colony Stimulating Factor ( GM-CSF ) -Producing GM.CD40L Autologous Tumor Vaccine Mantle Cell Lymphoma</brief_title>
	<detailed_description>Patients treat 3-6 cycle chemotherapy +/- rituximab , type duration discretion individual clinician . Evaluation response perform 1 month complete chemotherapy , include compute tomography ( CT ) scan , bone marrow biopsy , endoscopy , colonoscopy . Minimal residual disease ( MRD ) assess qualitatively bone marrow specimen use polymerase chain reaction ( PCR ) standardize primer evaluation B-cell receptor gene rearrangement . Responses define accord revise Cheson criterion . Patients successful lymph node harvest obtain complete partial response could proceed bystander vaccination . The GM.CD40L bystander vaccine administer intradermally bilateral axillary inguinal nodal basins via eight separate injection ( 0.125 ml / injection ) . Low dose IL-2 ( 0.5 x 10^6 unit ) give subcutaneously twice daily 14 day follow vaccination . Patients restaged CT and/or CT/PET bone marrow biopsy every 6 month , begin last date chemotherapy . Follow-up bone marrow biopsy evaluation include assessment MRD described . Patients without disease progression toxicity attributable vaccine eligible 4 monthly booster vaccine 12 month 24 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mantle cell lymphoma Stage II , III , IV disease Relapsed de novo disease No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy Not specify Hematopoietic White blood count ( WBC ) &gt; 3,000/mm^3 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hematocrit &gt; 25 % Hemoglobin &gt; 8 g/dL Hepatic Bilirubin &lt; 2.0 mg/dL Renal Creatinine &lt; 2.0 mg/dL OR Creatinine clearance &gt; 60 mL/min Immunologic No serious ongoing infection No known HIV infection No preexisting immunodeficiency condition Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month , , 3 month study treatment PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy More 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy More 4 week since prior steroid No concurrent corticosteroid except replacement dos patient hypoadrenal Radiotherapy More 2 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other No concurrent immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>